Putting aside the prostrate topic, this comment in the...

Putting aside the prostrate topic, this comment in the announcement is interesting............ “With our MagSense® HER2 imaging agent for breast cancer advancing in clinical testing, we have been expanding our R&D pipeline" To say the breast cancer imaging work is advancing can only be interpreted, surely, that there have been more recruitments. Its been a long time since the 5 were recruited and an announcement was made back then there was still insufficient data to make any determination as to the efficacy of the imaging. So, by now saying the imaging agent for breast cancer is advancing in the clinical trials can only mean one thing, unless its doublespeak.